Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-23
2006-05-23
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07049284
ABSTRACT:
Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described.
REFERENCES:
patent: 5432156 (1995-07-01), Matsuno et al.
patent: 5912229 (1999-06-01), Thim et al.
patent: 612531 (1994-08-01), None
J Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
SIGMA. Designing Custom Peptides. http://www.sigma-genosys.com/peptide—design.asp (Accessed Dec. 16, 2004). 2 pages.
Donald Voet, et al., Biochemistry, Second Edition, John Wiley & Sons, 1995, pp. 235-241.
HJC Berendsen. A Glimpse of the Holy Grail? Science (1998) 282. 642-643.
Barragan, et al., Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.American Journal of Physiology. 266 (3 Pt 1). pE459-66, Mar. 1994.
Bloom, et al., Gut Hormones in adaption.Gut.28, S1, pp. 31-35, 1987.
Brubaker, et al., Regulation of Intestinal Proglucagon-Derived Peptide Secretion by Intestinal Regulatory Peptides.Endocrinology.vol. 128, No. 6, pp. 3175-3182, 1991.
Buhl, et al., Naturally Occuring Products of Proglucagon 111-160 in the Porcine and Human Small Intestine.The Journal of Biological Chemistry.vol. 263, No. 18, pp. 8621-8624, Issue of Jun. 25, 1988.
Calvo, et al., Structural characterization by affinity cross-linking of glucagon-like peptide-1 (7-36) amide receptor in rat brain.J. Neurochem.64(1), pp. 299-306, Jan. 1995.
Cheeseman, et al., The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal basolateral membrane hexose transport.The American Physiological Society.APSracts 3:0071G, Apr. 16, 1996. (Abstract Only).
Drucker, et al.,Pancreas.1990, 5(4):484.
Ehrlich, et al., Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors.American Journal of Physiology.pp. E662-E671, 1994.
George, et al., Molecular forms of glucagon-like peptides in man.FEBS Letters.vol. 192, No. 2, pp. 275-278, Nov. 1985.
Hoosein, et al., Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase.FEBS Letters.vol. 178, No. 1, pp. 83-86, Dec. 1984.
Irwin, et al., Trout and Chicken Proglucagon: Alternative Splicing Generates mRNA Transcripts Encoding Glucagon-Like Peptide 2.Molecular Endocrinology.9:267-277, 1995.
Lee, et al., Glucagon Gene 5′-Flanking Sequences Direct Expression of Simian Virus 40 Large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice.The Journal of Biological Chemistry.vol. 267, No. 15, pp. 10706-10708, May 25, 1992.
Lund, et al., Regulation of Intestinal Glucagon Gene Expression during Adaptive Growth of Small Intestine.Digestion.54:371-373, 1993.
Mojsov, et al., Preproglucagon Gene Expression in Pancreas and Intestine Diversifies at the Level of Post-translational Processing.The Journal of Biological Chemistry.vol. 261, No. 25, pp. 11880-11889, Sep. 5, 1986.
Mommsen, et al., Glucagon-like peptides activate hepatic gluconeogenesis.FEBS Letters.vol. 219, No. 1, pp. 227-232, Jul. 1987.
Nishi, et al.,Mol. Endocrinol., 1990, 4:1192-8.
Orskov, et al., Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine.FEBS Letters.247(2). pp. 193-196, Apr. 24, 1989.
Orskov, et al., Pancreatic and intestinal processing of proglucagon in man.Diabetologia.30:874-881, 1987.
Orskov, et al., Radio-immunoassays for glucagon-like pepeptides 1 and 2 (GLP-1 and GLP-2).Scand. J. Clin. Lab. Invest.47(2). pp. 165-174, Apr. 1987.
Orskov, et al., Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pic Small Intestine by Not Pancreas.Endocrinology.vol. 119, No. 4, pp. 1467-1475, 1986.
Ruiz-Grand, et al. Renal catabolism of human glucagon-like peptides 1 and 2.Can. J. Physiol. Pharmacol.68 (12), pp. 1568-1573, Dec. 1990.
Shennan, et al, Proglucagon expression, post-translational processing and secretion in SV40-transformed islet cells.Molecular and Cellular Endocrinology.67(1989), pp. 93-99.
Watanabe, et al., Trophic Effect of Glucagon-(1-21)-Peptide on the Isolated Rat Ileal Mucosal Cells.Biochemical and Biophysical Research Communications.vol. 152, No. 3. pp. 1038-1044, May 16, 1988.
1149336 Ontario Inc.
Harle Jennifer
Tate Christopher R.
LandOfFree
Glucagon-like peptide-2 and its therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon-like peptide-2 and its therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon-like peptide-2 and its therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536888